CBLS Genomics & Bioinformatics Core (GBC) Helps Evolve Molecular Diagnostics Industry: The Story of Rheonix

Rheonix®, Inc. has created a powerful microfluidic platform for the evolving molecular diagnostics industry that miniaturizes and automates all the functions of a molecular biology lab on a disposable chip the size of the palm of your hand. The Rheonix CARD® (Chemistry And Reagant Device) system incorporates disposable microfluidic chip technology and a scalable automated platform to analyze single or multiple clinical raw samples, providing multiplexed endpoint and/or real time analysis for a wide array of diagnostic applications.

Successful pilot programs have applied the Rheonix CARD® system to a broad range of functional assays including immunoassay,pathogen identification, pharmacogenomic, companion diagnostics and other molecular diagnostic applications. Rheonix has established worldwide corporate, governmental and educational partnerships for new and existing assays. Commercial development projects include a multiplex assay for multiple sexually transmitted viruses, pharmacogenomic and companion diagnostic tests, human papillomavirus (HPV) detection, HIV antibody and viral RNA detection, drinking water and recreational water testing and other molecular diagnostic applications.

In collaboration with Co-Director of the CBLS's Genomics & Bioinformatics Core (GBC), Michael Buck, PhD, Rheonix will focus on automating Illumina's Nextera DNA Sample Preparation process to allow each of the individual steps to be seamlessly and automatically performed on the Rheonix CARD platform. Rheonix will investigate each of the individual steps int eh process including DNA isolation, tagmentation, clean up and limited-cylce PCR to amplify the resulting library for cluster generation on the Illumina platform. Rheonix will then provide that material to Dr. Buck's laboratory for further processing and testing. If successful, the Rheonix card will provide a means to reduce the time and cost of NGS library preparation methods.

In addition to the ongoing collaboration with the GBC, Rheonix gained funding assistance through the UB CAT program and Senior Vice President for Scientific and Clinical Affairs Dr. Richard Montagna, has not only attended but was a featured guest speaker at the CBLS Commercialization Lecture Series.